A PYMNTS Company

FTC v. Actavis and the Future of Reverse Payment Cases

By  |  May 10, 2021

By Joshua D. Wright (George Mason University)

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The Supreme Court ruled in FTC v. Actavis that reverse payment settlement agreements between branded and generic pharmaceutical companies are subject to antitrust scrutiny and should be analyzed under the traditional, but not necessarily full-blown, rule-of-reason. The Court’s decision represents a significant victory for the Commission because it brings these agreements firmly within the scope of the antitrust laws and rejects the “scope of the patent” test. A critical next step is to begin to answer the important questions left open by Actavis. For instance, what legal burdens and presumptions will lower courts apply when analyzing reverse payment settlement agreements under the rule-of-reason?

    Continue Reading…